Dara biosciences had just escaped being delisted in July of this year, now with a new batch of fresh revenue and some test fresh test results, DARA has been granted a fresh 180 day extension by the NASDAQ to comply with the 1.00 share limit. The companies back is against the wall and they have just released promising phase 2 results for their diabetes medication. The big whammy should come on the 19th when they present their KRN5500 pain medication phase 2 results, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain which will be held in San Francisco. They need to increase their revenue to 1.00 per share by Feb of 2010 or they will be delisted, they have promising results on one medication and they don't schedule phase 2 results for an international confrence to drop them on their own toes, so if you look at it DARA might have dynamite to present. I say they are a buy.
See these articles for more:
<font> http://phx.corporate-ir.net/phoenix.zhtml?c=219408&p=irol... = </font>
and
<font> http://phx.corporate-ir.net/phoenix.zhtml?c=219408&p=irol... </font>
Happy Stocking
$0.417 (11/12/09)
